18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling.
about
Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed EvidenceAdvances in Our Understanding of Oxylipins Derived from Dietary PUFAsEffect of Different Omega-6/Omega-3 Polyunsaturated Fatty Acid Ratios on the Formation of Monohydroxylated Fatty Acids in THP-1 Derived MacrophagesShort-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial)The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 miceDual Roles of Group IID Phospholipase A2 in Inflammation and CancerOmega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.A hybrid strategy using global analysis of oxidized fatty acids and bioconversion by Bacillus circulans.Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements.Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics.Eicosapentaenoic acid and 5-HEPE enhance macrophage-mediated Treg induction in mice.Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization.Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study.Quantitative Profiling of Hydroxy Lipid Metabolites in Mouse Organs Reveals Distinct Lipidomic Profiles and Modifications Due to Elevated n-3 Fatty Acid Levels.Spectrum evaluation-assisted eicosanoid metabolomics for global eicosanoid profiling in human vascular endothelial cells.Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs.Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial.A Randomized Trial of Effects of Alcohol on Cytochrome P450 Eicosanoids, Mediators of Inflammation Resolution, and Blood Pressure in Men.Maternal dietary n-6 polyunsaturated fatty acid deprivation does not exacerbate post-weaning reductions in arachidonic acid and its mediators in the mouse hippocampus.12-OH-17,18-Epoxyeicosatetraenoic acid alleviates eosinophilic airway inflammation in murine lungs.Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice.Atherosclerosis, Periodontal Disease, and Treatment with Resolvins.Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.Comprehensive analysis of the mouse cytochrome P450 family responsible for omega-3 epoxidation of eicosapentaenoic acid.ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
P2860
Q26798057-D1BDCD97-C09F-4C53-BBE5-689450EB66FEQ27014988-C9170D1E-9A12-48A0-90B4-5D1354DFB2FBQ28383078-9118F207-808E-46B7-8AB6-80BE3DBCC8D6Q36141602-FA286AB3-C2CA-41F6-BA94-DDDA1D0E087AQ36257833-1EA90F7A-8BA7-4E67-809F-40D076E31E38Q37117284-90F46AAB-5D47-43A5-9ECC-C5DAA5ED5F14Q38680756-3589C9D6-728C-4F13-9939-FE78FFC053AAQ40006798-E2D01E3B-1B10-467D-BA62-E03CCE107F67Q40094392-03DCC281-2C7C-4B45-9D2F-A7808D4B62E8Q40317977-0B37DB93-797E-435B-A783-C7BC565C69F3Q40965932-043F3966-E39C-4297-AB8C-607DBBF823B0Q41102448-F64431E7-622A-4940-B382-FA6ABE0C1C62Q41716070-042E7C75-F033-4AEA-A076-9101B7F61C79Q42176297-B9CE833F-0251-4D8F-8939-E9FB6ED7F9ABQ42513014-536FA035-42D8-45A4-A3C9-E7C98BDBD4D6Q42517703-834D37F7-2C01-497E-A3DB-98B1AD84EA3EQ45064553-3262FEE2-8D4D-4746-AE53-38DA3B9BA054Q47367164-62D65E38-1426-4B8C-A574-1C2332905D12Q47947231-FF1CBB2A-9F1A-4829-9D67-3E85CA89E3A6Q48114593-2332DB23-2D07-44AD-8BDE-E40C95A1D062Q48149763-009865FC-C883-45D6-B620-3AF0218AE87BQ48192095-3453A026-3F24-468A-BADD-755BD7BF3125Q49337769-3D062DFE-C0A9-477D-96B8-4B054EE8FADEQ50129587-3D168B25-ED7C-4F39-BB63-5B1A153401E1Q52369219-C690CADC-2196-43ED-BFE3-4811468ADC23Q55312555-91FF3DCC-B857-4D3F-A3FB-CA7DF28DC80EQ59135574-DCA0260D-EB98-47C3-9A4F-DF90AE03C94C
P2860
18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
18-HEPE, an n-3 fatty acid met ...... aladaptive cardiac remodeling.
@en
type
label
18-HEPE, an n-3 fatty acid met ...... aladaptive cardiac remodeling.
@en
prefLabel
18-HEPE, an n-3 fatty acid met ...... aladaptive cardiac remodeling.
@en
P2093
P2860
P356
P1476
18-HEPE, an n-3 fatty acid met ...... aladaptive cardiac remodeling.
@en
P2093
Hiroyuki Arai
Jing X Kang
Keiichi Fukuda
Makoto Arita
Motoaki Sano
Yosuke Isobe
P2860
P304
P356
10.1084/JEM.20132011
P407
P577
2014-07-21T00:00:00Z